AstraZeneca's Wainua fails primary endpoint in ATTR-CM Phase III trial
The CARDIO-TTRansform Phase III trial for Wainua (eplontersen) did not meet its primary efficacy endpoint.
Phase III
Cardiology / ATTR-CM
Status
Active
Sponsor
AstraZeneca
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The failure of the CARDIO-TTRansform Phase III trial for Wainua is significant as it jeopardizes AstraZeneca and Ionis' position in the ATTR-CM market. This outcome necessitates a reassessment of the product's viability and potential strategic pivots to maintain competitive advantage.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor for further data releases, potential adjustments in trial design, and competitor responses in the ATTR-CM space.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.